ALHC stock forecast, quote, news & analysis
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans... Show more
Why Alignment Healthcare (ALHC) Stock Is Down -43% in the Last 30 Days
Key Takeaways
- Alignment Healthcare shares fell approximately 43% in the 30 days through October 9, 2026, sliding from a $13.03 close on September 9 to roughly $7.39.
- The decline was driven chiefly by a September 15 disclosure at Baird's Global Healthcare Conference and a subsequent CMS Medicare Advantage Star Ratings downgrade on the company's largest contract.
- The broader trend is even steeper, with shares down roughly 65% from about $21 per share in early July.
- Key pressures include rising medical costs, a lower 2027 Star Rating on the California H3815 HMO contract, analyst price-target cuts, and investor-rights investigations.
- Management has reaffirmed its guidance and characterized the issues as near-term "transformation noise" rather than a fundamental deterioration of the business.
Alignment Healthcare (ALHC) Company Overview and Market Position
Alignment Healthcare, Inc. is a technology-enabled Medicare Advantage insurer focused on serving Medicare-eligible seniors. The company combines a proprietary data and analytics platform with a high-touch, culturally responsive clinical care model, offering HMO, PPO, and special needs plans across states including California, Arizona, Nevada, North Carolina, and Texas.
Its competitive positioning rests on care coordination and population-health management aimed at improving outcomes while controlling medical costs. The company competes in the Medicare Advantage market alongside larger diversified insurers such as UnitedHealth and Humana. Investors track the stock closely because of its strong membership and revenue growth, its progress toward profitability, and the Star Ratings that drive bonus revenue for Medicare Advantage plans.
Alignment Healthcare (ALHC) Stock Price Performance: Last 30 Days vs. Quarter
Over the 30 days through October 9, 2026, ALHC fell from a closing price of $13.03 on September 9 to approximately $7.39, a decline of about 43%. The move included two sharp legs lower: a multi-day slide in mid-September and a further drop in early October that pushed shares to a new 52-week low.
The quarterly picture is even more pronounced. In early July, shares traded near $21, meaning the stock has lost roughly 65% over the past three months as a series of negative catalysts compounded.
What Drove ALHC Stock Price in the Last 30 Days
The most immediate catalyst came on September 15, 2026, when management presented at Baird's Global Healthcare Conference. Executives disclosed an additional $10 million to $11 million in planned second-half investments and flagged emerging medical-cost headwinds, including hospital billing practices, disputes, appeals, and skilled-nursing-facility pressure. The stock fell roughly 20% over the following two sessions on sharply elevated volume.
In early October, the Centers for Medicare & Medicaid Services (CMS) released 2027 Star Ratings that downgraded the company's California H3815 HMO contract from 4.0 to 3.5 stars. Because that contract holds more than 75% of the company's membership and Medicare Advantage plans generally need a 4-star rating to qualify for bonus payments, the downgrade weighed heavily on sentiment. Analysts noted that the share of enrollment in 4-star-or-better plans dropped from about 98% to roughly 24%, and JPMorgan lowered its price target to $10 from $22 while maintaining an Overweight rating.
Alignment has disputed the accuracy of the 3.5-star score and said it intends to pursue administrative remedies and litigate measures it believes warrant review. Separately, law firms including Hagens Berman and Rosen announced investigations, citing a whistleblower complaint alleging misclassification of operating expenses as capital expenditures.
What Drove ALHC Stock Performance Over the Last Quarter
The quarterly decline reflects more than short-term headlines. On July 30, 2026, the company reported second-quarter revenue that fell short of expectations and offered guidance implying only about 30% of full-year adjusted EBITDA would arrive in the second half, sending shares down more than 20% the following day.
That earnings shock was followed by the September conference disclosures and the October Star Ratings release, compounding investor concerns about medical-cost trends, reserve adequacy, and the durability of the company's growth-to-profitability trajectory. Broader managed-care sector pressure added to the negative backdrop as peers faced similar scrutiny around Stars, risk adjustment, and medical utilization.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only top-performing and most relevant bots appear in this featured section. These bots vary in strategy, timeframe, and performance metrics, so traders can review different approaches before committing to one. For those looking to monitor market signals alongside their own analysis, the Trending AI Robots page is a useful starting point.
ALHC Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape the stock's direction in the coming quarters. Investors will monitor the company's third-quarter earnings report for any change to full-year guidance and for evidence on whether institutional and hospital cost pressures are easing. The outcome of the company's planned appeals and litigation over its Star Ratings methodology, and any revision to CMS scoring, could materially affect future bonus revenue.
Additional items to watch include medical-cost trends across Medicare Advantage, the 2028 bid cycle and planned new-state expansion, reserve adequacy for 2025 and 2026 dates of service, and the resolution of pending investor-rights investigations. Regulatory developments around Stars and risk adjustment also remain important for the entire sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALHC in +4.06% Uptrend, rising for three consecutive days on October 08, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ALHC advanced for three days, in 252 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALHC's RSI Oscillator exited the oversold zone, 25 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for ALHC just turned positive on October 02, 2026. Looking at past instances where ALHC's MACD turned positive, the stock continued to rise in 29 of 41 cases over the following month. The odds of a continued upward trend are 71%.
ALHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALHC as a result. In 65 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ALHC entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALHC's P/B Ratio (6.203) is slightly higher than the industry average of (3.247). P/E Ratio (41.737) is within average values for comparable stocks, (139.958). ALHC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.389) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ALHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ManagedHealthCare